OOIR: Observatory of International Research

Papers

(The H4-Index of JACC: Cardiooncology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Cardiovascular Risk Factors Are Associated With Future Cancer	99
Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification	97
Cardiovascular Manifestations From Therapeutic Radiation	88
Venous and Arterial Thromboembolism in Patients With Cancer	86
ATTR Amyloidosis: Current and Emerging Management Strategies	83
The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity	79
Incident Cardiovascular Disease Among Adults With Cancer	72
Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis	70
Risk of Atrial Fibrillation According to Cancer Type	68
Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation	67
Strain Imaging in Cardio-Oncology	64
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity	61
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis	59
Immune Checkpoint Inhibitor Therapy in Oncology	58
Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors	54
Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury	51
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies	40
BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab	39
Arterial Thromboembolism in Cancer Patients	38
Electrophysiological Manifestations of Cardiac Amyloidosis	38
Genetics of Anthracycline Cardiomyopathy in Cancer Survivors	35
Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort	34
Atherosclerosis With Immune Checkpoint Inhibitor Therapy	33
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer	33
Risk of Cancer After Diagnosis of Cardiovascular Disease	33

AL Amyloidosis for Cardiologists	32
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm	32
Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer	32
Does Cardiovascular Mortality Overtake Cancer Mortality During Cancer Survivorship?	31
Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity	31
Low QRS Voltages in Cardiac Amyloidosis	31